Here's How to Break Through - REJUV, accessed April 23, 2025, Wegovy timeline: what to expect - Numan, accessed April 23, 2025, Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes, accessed April 23, 2025, Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and MetaAnalysis of Direct Comparative Studies - PubMed Central, accessed April 23, 2025, SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial, accessed April 23, 2025, Lilly's tirzepatide superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs
The GLP-1 market is not winner-take-all
Another potential risk factor that may be present in an increasing number of patients is hepatic steatosis or steatohepatitis caused by obesity, type 2 diabetes, and poor diet [180]
A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region
When fatigue lingers, people naturally move less
Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia